Amicus Therapeutics Inc (FOLD)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

1 CEDAR BROOK DRIVE CRANBURY, NJ 08512

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The pharmacological chaperone technology involves the use of small molecules to restore biological activity in cells by binding to a misfolded protein caused by a genetic mutation. The company is targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Its lead compound includes Amigal, which is in Phase II clinical trials is used for the treatment of Fabry disease that causes kidney failure, cardiac abnormalities, and neurological complications. The company is also developing AT2101 for the treatment of Gaucher disease, which causes an enlarged liver and spleen, low levels of red blood cells and platelets, bone pain, and fractures; and AT2220 for the treatment of Pompe disease, which causes muscle weakness primarily affecting breathing, mobility, and heart function. The company has a strategic collaboration with Shire Human Genetic Therapies, Inc. to jointly develop pharmacological chaperone compounds for lysosomal storage disorders.

Data based on most recent fiscal year report
Market Cap2.186 Billion Shares Outstanding166.27 Million Avg Volume4.925 Million
1-Yr BETA vs S&P TR Current Ratio5.6 Quick Ratio5.53
View SEC Filings from FOLD instead.
Q2 2019 All Institutions Hedge Funds 1
To trade FOLD now:
Filers who had this stock in their top 10: 9 6 (0.62%)
13F Filers holding this stock: 199 42 (4.34%)
Aggregate 13F shares on 06/30/2019: 267.042 Million 88.585 Million
Aggregate 13F shares on 03/31/2019: 249.06 Million 82.924 Million
Percent change: 7.22% 6.83%
Funds creating new positions: 39 13
Funds Adding to an existing position: 90 14
Funds closing out their position: 36 9
Funds reducing their position: 36 6
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding FOLD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

4.9 Thousand total shares from 1 transactions

Open Market Sells (S)

34.5 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

20 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CROWLEY JOHN F CHAIRMAN & CEO

  • Officer
  • Director
800,589 2019-10-11 13

CLARK DAVID MICHAEL CHIEF PEOPLE OFFICER

  • Officer
101,161 2019-10-09 2

REDMILE GROUP, LLC

GREEN JEREMY

  • 10% Owner
2,268,718 2019-10-07 0

MCGLYNN MARGARET G

  • Director
0 2019-09-30 1

TOPPER JAMES N

  • Director
0 2019-09-30 0

PERCEPTIVE ADVISORS LLC

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

EDELMAN JOSEPH

  • 10% Owner
45,951,556 2019-09-23 0

LOVE TED W

  • Director
8,294 2019-09-18 1

GLAXOSMITHKLINE PLC

  • Director
2,170,327 2019-09-10 0

ANDREWS KURT J. CHIEF HUMAN RESOURCES OFFICER

  • Officer
0 2019-09-06 0

PATTERSON MATTHEW R CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
285,208 2019-09-05 0

BLOCH STEPHEN M

  • Director
0 2019-08-29 0

WHITMAN BURKE W

  • Director
21,612 2019-08-23 3

BARER SOL J

  • Director
0 2019-08-13 0

WHEELER CRAIG A PRESIDENT & CEO

  • Officer
  • Director
512,797 2019-08-12 1

BALDRY MARK CHIEF COMMERICAL OFFICER

  • Officer
39,000 2019-08-05 0

BLEIL LYNN DORSEY

  • Director
0 2019-07-31 1

BARRIS PETER J

  • 10% Owner
4,186,243 2019-07-22 0

CAMPBELL BRADLEY L

0 2019-07-11 3

GILMORE GEOFFREY GENERAL COUNSEL

  • Officer
0 2019-07-03 0

RAAB MICHAEL

  • Director
15,145 2019-06-27 2

SBLENDORIO GLENN

  • Director
28,078 2019-06-27 1

ESSNER ROBERT

  • Director
15,145 2019-06-27 1

QUIMI DAPHNE CHIEF FINANCIAL OFFICER

  • Officer
129,254 2019-06-17 3

BARTH JAY CHIEF MEDICAL OFFICER

  • Officer
148,520 2019-06-17 6

DO HUNG CHIEF SCIENCE OFFICER

  • Officer
457,401 2019-06-14 4

ROSENBERG ELLEN CHIEF LEGAL OFFICER

  • Officer
168,465 2019-06-14 3

SCHAEFFER ORLOV S NICOLE CHIEF PEOPLE STRATEGY OFFICER

  • Officer
24,350 2019-06-06 0

HAYDEN DONALD J JR

0 2019-05-31 0

BARRETT M JAMES

  • Director
0 2019-05-30 0

DENTZER JAMES E PRESIDENT & CEO

  • Officer
  • Director
0 2019-05-23 0

BAIRD WILLIAM D III

  • Director
0 2019-05-22 0

KRAMLICH C RICHARD

  • Director
0 2019-05-20 0

PROUT SAMANTHA PRINCIPAL ACCOUNTING OFFICER

  • Officer
11,417 2019-03-26 2

NEFF P SHERRILL

  • Director
23,839 2019-03-08 0

NEWHALL CHARLES W III

  • Director
92,298 2019-02-22 0

BOUDES POL F CHIEF MEDICAL OFFICER

  • Officer
0 2019-01-29 0

WEINHOFF GREGORY M PRINCIPAL FINANCIAL OFFICER

  • Officer
0 2018-03-15 0

WINTERBOTTOM JOAN CHIEF HUMAN RESOURCES OFFICER

  • Officer
47,248 2017-01-19 0

PEIST KENNETH VP, LEGAL & IP

  • Officer
18,874 2016-01-04 0

VALENZANO KEN SVP, PHARMACOLOGY & BIOLOGY

  • Officer
27,687 2015-07-13 0

DOSHI DIPAL SVP STRATEGY & BUS DEV

  • Officer
1,706 2015-07-07 0

GERSHKOWITZ JAYNE SVP, CHIEF PATIENT ADVOCATE

  • Officer
5,693 2015-07-01 0

CASTELLI JEFF SVP, PROGRAM MANAGEMENT

  • Officer
25,000 2015-06-22 0

DILONE ENRIQUE SVP, TECHNICAL OPERATIONS

  • Officer
30,688 2015-06-19 0

YU JULIE VP CLINICAL OPS & DATA MGMT

  • Officer
0 2015-06-15 0

KIRK JOHN VP, REGULATORY AFFAIRS

  • Officer
0 2015-06-01 0

DAVID ALLSOP SVP INTERNATIONAL

  • Officer
0 2015-04-27 0

LOCKHART DAVID J CHIEF SCIENTIFIC OFFICER

  • Officer
0 2013-06-18 0

MACALUSO PETER M VP & CORPORATE COUNSEL

  • Officer
0 2013-06-18 0

PERRY MARK W

  • 10% Owner
0 2012-10-17 0

WINKLER ROBERT E VP, CLIN RESEARCH & OPERATIONS

  • Officer
0 2012-06-04 0

NEW ENTERPRISE ASSOCIATES 11 LP

NEA PARTNERS 11 LP

NEA 11 GP, LLC

BASKETT FOREST

DRANT RYAN D

KOLLURI KRISHNA KITTU

SANDELL SCOTT D

  • 10% Owner
4,584,311 2012-03-07 0

BARKAS ALEXANDER E

  • Director
0 2011-05-24 0

JOHN MCADAM M VP, FINANCE & ACCOUNTING

  • Officer
0 2010-06-15 0

PALLING DAVID SR VP, TECHNICAL OPERATIONS

  • Officer
34,040 2009-06-26 0

LICHOLAI GREGORY P VP, MEDICAL AFFAIRS

  • Officer
0 2009-02-03 0

SHENKER ANDREW VP, CLINICAL RESEARCH

  • Officer
0 2009-02-03 0

FHM IV LP

FRAZIER HEALTHCARE V, LP

FHM V, LP

FHM V, LLC

FRAZIER HEALTHCARE IV LP

FRAZIER AFFILIATES IV LP

  • 10% Owner
915,924 2008-03-06 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2019-10-11 S 14,500 $8.01 d 735,694 800,589.00 direct yes

CLARK DAVID MICHAEL - Officer CHIEF PEOPLE OFFICER

2019-10-09 F 6,896 $7.48 d 101,161 101,161.00 direct

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2019-09-11 S 20,000 $10.05 d 750,194 815,089.00 direct yes

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2019-09-11 M 20,000 $3.82 a 770,194 815,089.00 direct

CROWLEY JOHN F - Director - Officer CHAIRMAN & CEO

2019-09-11 M 20,000 d 91,439 815,089.00 direct

WHITMAN BURKE W - Director

2019-08-23 P 4,945 $10.07 a 21,612 21,612.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments